AU Patent

AU2020397917A1 — GLP2 receptor agonists and methods of use

Assigned to Scripps Research Institute · Expires 2022-06-23 · 4y expired

What this patent protects

Peptide conjugates comprising a peptide that modulates the GLP-2 receptor are provided. The peptide conjugates may be used for treating conditions responsive to modulation of the GLP-2 receptor. Further provided are stapled GLP-2 peptide conjugates.

USPTO Abstract

Peptide conjugates comprising a peptide that modulates the GLP-2 receptor are provided. The peptide conjugates may be used for treating conditions responsive to modulation of the GLP-2 receptor. Further provided are stapled GLP-2 peptide conjugates.

Drugs covered by this patent

Patent Metadata

Patent number
AU2020397917A1
Jurisdiction
AU
Classification
—
Expires
2022-06-23
Drug substance claim
No
Drug product claim
No
Assignee
Scripps Research Institute
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.